The Journal of Thoracic and Cardiovascular Surgery
Volume 140, Issue 2 , Pages 440-446 , August 2010

Activation of A1, A2A, or A3 adenosine receptors attenuates lung ischemia-reperfusion injury

  • Leo M. Gazoni, MD

      Affiliations

    • Department of Surgery, University of Virginia Health System, Charlottesville, Va
    • ,
  • Dustin M. Walters, MD

      Affiliations

    • Department of Surgery, University of Virginia Health System, Charlottesville, Va
    • ,
  • Eric B. Unger, BS

      Affiliations

    • Department of Surgery, University of Virginia Health System, Charlottesville, Va
    • ,
  • Joel Linden, PhD

      Affiliations

    • Department of Medicine, University of Virginia Health System, Charlottesville, Va
    • ,
  • Irving L. Kron, MD

      Affiliations

    • Department of Surgery, University of Virginia Health System, Charlottesville, Va
    • ,
  • Victor E. Laubach, PhD

      Affiliations

    • Department of Surgery, University of Virginia Health System, Charlottesville, Va
    • Corresponding Author InformationAddress for reprints: Victor E. Laubach, PhD, Department of Surgery, University of Virginia Health System, PO Box 801359, Charlottesville, VA 22908.

Received 20 August 2009 ,Revised 8 December 2009 ,Accepted 1 March 2010.

References 

  1. Christie JD, Edwards LB, Aurora P, Dobbels F, Kirk R, Rahmel AO, et al. The registry of the international society for heart and lung transplantation: twenty-sixth official adult lung and heart-lung transplantation Report-2009. J Heart Lung Transplant. 2009;28:1031–1049
  2. Ailawadi G, Lau CL, Smith PW, Swenson BR, Hennessy SA, Kuhn CJ, et al. Does reperfusion injury still cause significant mortality after lung transplantation?. J Thorac Cardiovasc Surg. 2009;137:688–694
  3. Fiser SM, Tribble CG, Long SM, Kaza AK, Kern JA, Jones DR, et al. Ischemia-reperfusion injury after lung transplantation increases risk of late bronchiolitis obliterans syndrome. Ann Thorac Surg. 2002;73:1041–1047
  4. Gazoni LM, Laubach VE, Mulloy DP, Bellizzi A, Unger EB, Linden J, et al. Additive protection against lung ischemia-reperfusion injury by adenosine A2A receptor activation before procurement and during reperfusion. J Thorac Cardiovasc Surg. 2008;135:156–165
  5. Reece TB, Ellman PI, Maxey TS, Crosby IK, Warren PS, Chong TW, et al. Adenosine A2A receptor activation reduces inflammation and preserves pulmonary function in an in vivo model of lung transplantation. J Thorac Cardiovasc Surg. 2005;129:1137–1143
  6. Sharma AK, Linden J, Kron IL, Laubach VE. Protection from pulmonary ischemia-reperfusion injury by adenosine A2A receptor activation. Respir Res. 2009;10:58
  7. Rivo J, Zeira E, Galun E, Matot I. Activation of A3 adenosine receptor provides lung protection against ischemia-reperfusion injury associated with reduction in apoptosis. Am J Transplant. 2004;4:1941–1948
  8. Todo S, Zhu Y, Zhang S, Jin MB, Ishizaki N, Tanaka H, et al. Attenuation of ischemic liver injury by augmentation of endogenous adenosine. Transplantation. 1997;63:217–223
  9. Sun CX, Zhong H, Mohsenin A, Morschl E, Chunn JL, Molina JG, et al. Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury. J Clin Invest. 2006;116:2173–2182
  10. Jacobson KA. Adenosine A3 receptors: novel ligands and paradoxical effects. Trends Pharmacol Sci. 1998;19:184–191
  11. Day YJ, Li Y, Rieger JM, Ramos SI, Okusa MD, Linden J. A2A adenosine receptors on bone marrow-derived cells protect liver from ischemia-reperfusion injury. J Immunol. 2005;174:5040–5046
  12. Cappellacci L, Franchetti P, Vita P, Petrelli R, Lavecchia A, Costa B, et al. 5'-Carbamoyl derivatives of 2'-C-methyl-purine nucleosides as selective A1 adenosine receptor agonists: affinity, efficacy, and selectivity for A1 receptor from different species. Bioorg Med Chem. 2008;16:336–353
  13. Brambilla R, Cattabeni F, Ceruti S, Barbieri D, Franceschi C, Kim YC, et al. Activation of the A3 adenosine receptor affects cell cycle progression and cell growth. Naunyn Schmiedebergs Arch Pharmacol. 2000;361:225–234
  14. Yaar R, Jones MR, Chen JF, Ravid K. Animal models for the study of adenosine receptor function. J Cell Physiol. 2005;202:9–20
  15. Neely CF, Keith IM. A1 adenosine receptor antagonists block ischemia-reperfusion injury of the lung. Am J Physiol. 1995;268(6 Pt 1):L1036–L1046
  16. Rivo J, Zeira E, Galun E, Einav S, Linden J, Matot I. Attenuation of reperfusion lung injury and apoptosis by A2A adenosine receptor activation is associated with modulation of bcl-2 and bax expression and activation of extracellular signal-regulated kinases. Shock. 2007;27:266–273
  17. Sullivan GW. Adenosine A2A receptor agonists as anti-inflammatory agents. Curr Opin Investig Drugs. 2003;4:1313–1319
  18. Linden J. Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol. 2001;41:775–787
  19. Yang Z, Cerniway RJ, Byford AM, Berr SS, French BA, Matherne GP. Cardiac overexpression of A1-adenosine receptor protects intact mice against myocardial infarction. Am J Physiol Heart Circ Physiol. 2002;282:H949–H955
  20. Kaminski PM, Proctor KG. Attenuation of no-reflow phenomenon, neutrophil activation, and reperfusion injury in intestinal microcirculation by topical adenosine. Circ Res. 1989;65:426–435
  21. Lee HT, Xu H, Nasr SH, Schnermann J, Emala CW. A1 adenosine receptor knockout mice exhibit increased renal injury following ischemia and reperfusion. Am J Physiol Renal Physiol. 2004;286:F298–F306
  22. Zheng J, Wang R, Zambraski E, Wu D, Jacobson KA, Liang BT. Protective roles of adenosine A1, A2A, and A3 receptors in skeletal muscle ischemia and reperfusion injury. Am J Physiol Heart Circ Physiol. 2007;293:H3685–H3691
  23. Zhong H, Shlykov SG, Molina JG, Sanborn BM, Jacobson MA, Tilley SL, et al. Activation of murine lung mast cells by the adenosine A3 receptor. J Immunol. 2003;171:338–345
  24. Polosa R. Adenosine-receptor subtypes: their relevance to adenosine-mediated responses in asthma and chronic obstructive pulmonary disease. Eur Respir J. 2002;20:488–496
  25. van der Hoeven D, Wan TC, Auchampach JA. Activation of the A(3) adenosine receptor suppresses superoxide production and chemotaxis of mouse bone marrow neutrophils. Mol Pharmacol. 2008;74:685–696
  26. Cross HR, Murphy E, Black RG, Auchampach J, Steenbergen C. Overexpression of A(3) adenosine receptors decreases heart rate, preserves energetics, and protects ischemic hearts. Am J Physiol Heart Circ Physiol. 2002;283:H1562–H1568
  27. Tracey WR, Magee WP, Oleynek JJ, Hill RJ, Smith AH, Flynn DM, et al. Novel N6-substituted adenosine 5'-N-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury. Am J Physiol Heart Circ Physiol. 2003;285:H2780–H2787
  28. Feoktistov I, Biaggioni I. Adenosine A2B receptors. Pharmacol Rev. 1997;49:381–402
  29. Cagnina RE, Ramos SI, Marshall MA, Wang G, Frazier CR, Linden J. Adenosine A2B receptors are highly expressed on murine type II alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2009;297:L467–74
  30. Feoktistov I, Biaggioni I. Adenosine A2b receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma. J Clin Invest. 1995;96:1979–1986

 This study was supported by National Institutes of Health R01HL092953 (to V.E.L. and I.L.K.), National Institutes of Health T32HL007849 (to I.L.K.), and the Roche Organ Transplant Research Foundation (to V.E.L.).

 Disclosures: Drs Linden and Kron were shareholders in Adenosine Therapeutics, LLC, the corporation that provided ATL-313, at the time of the study.

PII: S0022-5223(10)00232-1

doi: 10.1016/j.jtcvs.2010.03.002

The Journal of Thoracic and Cardiovascular Surgery
Volume 140, Issue 2 , Pages 440-446 , August 2010

Article Tools

* Image Usage & Resolution